| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.0M | — | — |
| R&D Expense | $34.1M | — | +23.8% |
| SG&A Expense | $12.4M | — | +58.6% |
| Operating Income | -$26.6M | — | +25.0% |
| Net Income | -$24.2M | — | +26.2% |
| EPS (Basic) | -$0.45 | — | +60.9% |
| EPS (Diluted) | -$0.45 | — | +60.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $198.8M | +5.0% | -32.5% |
| Short-term Investments | $153.6M | +0.6% | — |
| Accounts Receivable | $20.0M | — | — |
| Current Assets | $379.8M | +8.6% | +26.7% |
| Total Assets | $419.7M | +5.7% | +26.1% |
| Current Liabilities | $21.2M | -5.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$39.1M | — | -32.5% |
| Capital Expenditures | $93K | — | -68.9% |
| Investing Cash Flow | $6.3M | — | +2198.7% |
| Financing Cash Flow | $42.4M | — | -66.7% |
| Free Cash Flow | -$39.2M | — | -31.5% |
| +14.1% |
| Long-term Debt | $38.8M | — | — |
| Total Liabilities | $78.0M | +85.0% | +91.3% |
| Stockholders' Equity | $341.7M | -3.7% | +17.0% |